Compare FLY & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | GKOS |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | FLY | GKOS |
|---|---|---|
| Price | $26.17 | $180.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $38.88 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 3.2M | 824.9K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $174.79 | $23.32 |
| Revenue Next Year | $66.73 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $16.00 | $73.16 |
| 52 Week High | $62.17 | $184.00 |
| Indicator | FLY | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 73.86 |
| Support Level | $23.89 | $98.22 |
| Resistance Level | $24.35 | $184.00 |
| Average True Range (ATR) | 1.66 | 7.05 |
| MACD | 0.97 | 0.87 |
| Stochastic Oscillator | 90.07 | 65.96 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.